-Reuters
EF Hutton Initiates Coverage On Merus with Buy Rating, Announces Price Target of $35
EF Hutton analyst Tony Butler initiates coverage on Merus (NASDAQ:MRUS) with a Buy rating and announces Price Target of $35.
Biden Administration Plans To End Emergency Declarations On COVID-19 On May 11
-Reuters
Related Posts
Chardan Capital Maintains Neutral on Adverum Biotechnologies, Lowers Price Target to $3
Chardan Capital analyst Geulah Livshits maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Neutral and lowers the price target from $5 to $3.
Flotek Shares Down 5.18% On The Day, Traders Circulating Negative Seeking Alpha Blog Post From Contributor
http://seekingalpha.com/article/4028765-flotek-drilling-zero